Compare Quest Diagnostics Inc (DGX) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Mondaycom Ltd — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Mondaycom Ltd trades at $88.92 (market cap $3.76B). The key difference: Quest Diagnostics Inc is far larger — about 6.8× Mondaycom Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Mondaycom Ltd for 16 Days on average.
| DGX | MNDY | |
|---|---|---|
Market Cap | $25.48B | $3.76B |
Volume | 941,866 | 836,200 |
Sector | Health | Technology |
52-Week High | $247.45 | $205.24 |
52-Week Low | $173.49 | $58.81 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $31.23B | $2.92B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Monday.com (MNDY) trades at $88.96, up 6.53% in the last session, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company demonstrates robust revenue growth reaching $1.23 billion in 2025 with impressive 88.74% gross margins, though valuation multiples remain elevated with a P/E of 37.69. Recent news highlights the company's AI initiatives at its Elevate '26 conference and inclusion in multiple growth stock lists.
The outlook remains positive with Wall Street consensus at $108.64 target price and 65% buy ratings, though risks include competitive pressure from Meta's enterprise push and elevated valuation multiples. Earnings momentum continues with three consecutive quarterly beats, but investors should monitor the upcoming Q3 2026 results against $1.37 EPS expectations for continued validation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
